Lilly forecasts weak sales of weight-loss drug, shares slump
Eli Lilly's stock dropped 8% after forecasting fourth-quarter sales of its weight-loss drug Zepbound below Wall Street estimates, marking the second sales disappointment since its late 2023 launch.
Comentarios
Publicar un comentario
Leave a comment. Thanks!
Comentarios de Facebook